DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,737,293 | +160.1% | 551,716 | +152.9% | 0.19% | +163.9% |
| Q2 2023 | $52,561,569 | -9.3% | 218,134 | -5.3% | 0.07% | -15.3% |
| Q1 2023 | $57,939,551 | -7.1% | 230,321 | -2.3% | 0.08% | -12.4% |
| Q4 2022 | $62,388,549 | +55.0% | 235,633 | +53.1% | 0.10% | +49.2% |
| Q3 2022 | $40,258,000 | -7.0% | 153,881 | -11.1% | 0.06% | +1.6% |
| Q2 2022 | $43,268,000 | -29.8% | 173,003 | -15.9% | 0.06% | -16.9% |
| Q1 2022 | $61,619,000 | -13.2% | 205,601 | -4.4% | 0.08% | -9.4% |
| Q4 2021 | $70,971,000 | +8.9% | 215,096 | +2.1% | 0.08% | 0.0% |
| Q3 2021 | $65,171,000 | +20.0% | 210,642 | +4.1% | 0.08% | +16.4% |
| Q2 2021 | $54,310,000 | +65.8% | 202,376 | +39.3% | 0.07% | +52.1% |
| Q1 2021 | $32,758,000 | +31.0% | 145,244 | +29.0% | 0.05% | +20.0% |
| Q4 2020 | $25,009,000 | +21.6% | 112,583 | +16.1% | 0.04% | +2.6% |
| Q3 2020 | $20,565,000 | -34.4% | 96,971 | -46.7% | 0.04% | +18.2% |
| Q2 2020 | $31,366,000 | +168.5% | 181,900 | +115.1% | 0.03% | +17.9% |
| Q1 2020 | $11,684,000 | +51.3% | 84,564 | +67.4% | 0.03% | +86.7% |
| Q4 2019 | $7,724,000 | +75.1% | 50,502 | +65.0% | 0.02% | +50.0% |
| Q3 2019 | $4,410,000 | -2.4% | 30,614 | -3.1% | 0.01% | 0.0% |
| Q2 2019 | $4,517,000 | -84.3% | 31,587 | -85.5% | 0.01% | -83.3% |
| Q1 2019 | $28,721,000 | -59.0% | 217,551 | -68.0% | 0.06% | +3.4% |
| Q4 2018 | $70,077,000 | +46.7% | 679,575 | +54.6% | 0.06% | +13.7% |
| Q3 2018 | $47,760,000 | +141.6% | 439,560 | +119.4% | 0.05% | +8.5% |
| Q2 2018 | $19,768,000 | +2.0% | 200,320 | +1.2% | 0.05% | +2.2% |
| Q1 2018 | $19,388,000 | +28.4% | 198,023 | +21.7% | 0.05% | +27.8% |
| Q4 2017 | $15,098,000 | +15.7% | 162,663 | +6.9% | 0.04% | +16.1% |
| Q3 2017 | $13,047,000 | +32.3% | 152,102 | +30.2% | 0.03% | +24.0% |
| Q2 2017 | $9,858,000 | +54.6% | 116,809 | +56.7% | 0.02% | +47.1% |
| Q1 2017 | $6,375,000 | +17.6% | 74,534 | +7.0% | 0.02% | +21.4% |
| Q4 2016 | $5,420,000 | +14.2% | 69,636 | +15.1% | 0.01% | +16.7% |
| Q3 2016 | $4,744,000 | -56.5% | 60,517 | -43.9% | 0.01% | -25.0% |
| Q2 2016 | $10,894,000 | +147.1% | 107,860 | +132.1% | 0.02% | +23.1% |
| Q1 2016 | $4,409,000 | -0.8% | 46,480 | -2.9% | 0.01% | -13.3% |
| Q4 2015 | $4,446,000 | +20.2% | 47,868 | +10.3% | 0.02% | +7.1% |
| Q3 2015 | $3,698,000 | -5.1% | 43,403 | -4.7% | 0.01% | 0.0% |
| Q2 2015 | $3,898,000 | -0.8% | 45,546 | -1.6% | 0.01% | 0.0% |
| Q1 2015 | $3,929,000 | +4.1% | 46,277 | +5.1% | 0.01% | 0.0% |
| Q4 2014 | $3,774,000 | -9.5% | 44,029 | -19.8% | 0.01% | -17.6% |
| Q3 2014 | $4,171,000 | -45.7% | 54,900 | -43.7% | 0.02% | -46.9% |
| Q2 2014 | $7,676,000 | +1.0% | 97,493 | -3.8% | 0.03% | -8.6% |
| Q1 2014 | $7,598,000 | +21.4% | 101,312 | +25.0% | 0.04% | +12.9% |
| Q4 2013 | $6,259,000 | +15.4% | 81,074 | +3.6% | 0.03% | +3.3% |
| Q3 2013 | $5,426,000 | +9.5% | 78,275 | -0.0% | 0.03% | -3.2% |
| Q2 2013 | $4,957,000 | – | 78,309 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |